JOHNSTON, R.I., Sep 7, 2004 /PRNewswire-FirstCall via COMTEX/ -- "Micro Laboratories, Inc. (MLAR) is pleased to announce the appointment of Todd Davis as interim Chief Executive Officer and new member of the Board of Directors," stated Robert Thistle, current CEO. "Mr. Davis brings vast experience and knowledge in investment banking, distribution, sales and marketing to the company. One of the things that Micro Laboratories, Inc. has lacked is marketing capability and financial resources, but has been very strong in technology and product development. Mr. Davis should fill the gap and allow Micro Laboratories, Inc. to achieve growth and success. I will remain as Chief Scientific Officer, in charge of product and technology development, and Chairman of the Board of Directors."
Todd Davis stated, "Rarely does an opportunity in small public companies arise where the product line is fully developed, the technology is superior to the competitors and the product can benefit nearly every consumer. Sublingual delivery through the line of MicroSpray(R) vitamins, minerals and nutritional supplements produced by Micro Laboratories, Inc., offers maximum absorption, ease of use, a pleasant taste, and is the most convenient, effective and efficient method of administering vitamins and nutrients. Additionally, the product has mass appeal to key markets worldwide: children, seniors, nutritionally deficient, gastro-intestinally challenged, and the mainstream population who need and desire a better way to take their vitamins. I am pleased to accept this appointment, and intend to maximize shareholder value and create global market awareness for the complete line of MicroSpray(R) products."
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.